Alexandria Real Estate Equities Inc(ARE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | - | EPS (ttm) | -6.06 | Insider Own | 2.39% | Shs Outstand | 170.7M | Perf Week | -2.94% |
| Market Cap | 8.91B | Forward P/E | - | EPS next Y | -160.58% | Insider Trans | 0.51% | Shs Float | 170.1M | Perf Month | 6.41% |
| Enterprise Value | 25.34B | PEG | - | EPS next Q | -0.03 | Inst Own | 99.19% | Short Float | 4.29% | Perf Quarter | -3.09% |
| Income | -1.03B | P/S | 3.14 | EPS this Y | 117.96% | Inst Trans | 2.95% | Short Ratio | 4.03 | Perf Half Y | 1.77% |
| Sales | 2.84B | P/B | 0.56 | EPS next 5Y | 51.99% | ROA | -2.86% | Short Interest | 7.30M | Perf YTD | 4.5% |
| Book/sh | 91.1 | P/C | 18.75 | EPS past 3/5Y | - | ROE | -6.3% | 52W High | -42.04% ($88.24) | Perf Year | -39.65% |
| Cash/sh | 2.73 | P/FCF | 6.96 | Sales past 3/5Y | 5.34% 9.93% | ROIC | -3.62% | 52W Low | 29.76% ($39.41) | Perf 3Y | -54.54% |
| Dividend Est. | $2.88 (5.63%) | EV/EBITDA | 12.38 | EPS Y/Y TTM | -4485.62% | Gross Margin | 23.41% | Volatility(W/M) | 3.19% 3.43% | Perf 5Y | -73.96% |
| Dividend TTM | 3.48 | EV/Sales | 8.92 | Sales Y/Y TTM | -8.4% | Oper. Margin | 27.28% | ATR (14) | 1.82 | Perf 10Y | -51.08% |
| Dividend Ex-Date | 2026/9/30 | Quick Ratio | 1.57 | EPS Q/Q | 33.01% | Profit Margin | -36.32% | RSI (14) | 50.34 | Recom | 3.06 |
| Dividend Gr. 3/5Y | -0.28% 1.99% | Current Ratio | 1.57 | Sales Q/Q | -13.03% | SMA20 | -0.16% ($51.22) | Beta | 1.17 | Target Price | $53 |
| Payout | - | Debt/Eq | 0.85 | Earnings | 2026/8/3 | SMA50 | 1.35% ($50.46) | Rel Volume | 1.21 | Prev Close | $49.56 |
| Employees | 514 | LT Debt/Eq | 0.83 | EPS/Sales Surpr. | -557.93% 38.37% | SMA200 | 1.99% ($50.14) | Avg Volume(3M) | 1.81M | Price | $51.14 |
| IPO | 1997/5/23 | Option/Short | Yes/Yes | Trades | 16374 | Volume | 2,190,738 | Change | 3.19% |
Company
ARE is a Real Estate sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US office-focused REIT that owns and leases laboratory and office space tailored for life sciences and biotechnology tenants. Its performance is driven by demand from biotech tenants and interest rate trends.
Over the past 1 year, on the lower side
42% below its 1-year high.
Next ex-dividend (upcoming)
Ex-dividend September 30
ARE has weak earning power
27.28% of revenue is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +118.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 2 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -54.5% if bought 5 years ago.
Tap to view numbers
Dividends are paid consistently
Pays 5.63% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 99.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
It ranks #2 in the industry
Based on market cap of $9B.
FAQ
What kind of company is ARE?
ARE belongs to the Real Estate sector and operates in the REIT - Office industry.
What is the market cap of ARE?
The market cap of ARE is approximately $8.9B, ranking 1,020 within its sector.
Does ARE pay dividends?
ARE has a dividend yield of approximately 5.63%, with an annual dividend of $2.88.
What is the 52-week high and low for ARE?
ARE has recorded a 52-week high of $88.24 and a low of $39.41.